Explore how TYK2 inhibitors reshape psoriasis care, as experts weigh comorbidities, infection screening, and treat-to-target goals to overcome real-world treatment hurdles.
Optimizing Psoriasis Management with TYK2 Inhibitors
Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.
Discover how oral TYK2 inhibitors deliver targeted psoriasis control with strong safety data and biologic-like clearance, including insights on deucravacitinib and zasocitinib.
Psoriasis care shifts beyond skin: treat-to-target goals, heart risk reduction, and new oral TYK2 pills with strong safety data.
New oral psoriasis therapy delivers biologic-level skin clearance in tough patients, with PASI 100 rising to 42% by week 24.
Experts explain how deucravacitinib eases psoriasis itch fast, boosts quality of life, and why TB testing and boxed warnings matter.
Derm experts compare TYK2 pills with biologics for psoriasis—safety, speed, infections, and when combination therapy helps stubborn skin and joints.
Explore how cutting inflammation in psoriasis may lower heart risks, and why new oral TYK2 inhibitors could broaden treatment beyond injections.
Learn how dermatologists tailor psoriasis treatment—topicals, phototherapy, pills or biologics—using shared decisions, severity and comorbidities.
Learn how to personalize systemic psoriasis care, weigh comorbidities, and aim for rapid clearance to reduce heart and joint risks.
Advertisement
Advertisement
Trending on HCPLive
1
Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD
2
Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial
3
Q&A: How Lifelong Burdens Are Shaped by Childhood Eczema, With Delphine Kerob, MD
4
FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation
5